Futura Medical (FUM.L)

Executive Summary

Futura Medical is a UK-based specialty pharmaceutical company focused on the development and commercialization of innovative sexual health products. Its lead product, Eroxon (MED2005), is a topical gel for erectile dysfunction that has successfully completed Phase 3 clinical trials. The company leverages its proprietary drug delivery technology to create fast-acting, well-tolerated formulations. With a strong intellectual property portfolio and a clear commercial strategy, Futura is well-positioned to capture a significant share of the global sexual health market. The company's recent focus has been on securing regulatory approvals and establishing commercial partnerships to drive product adoption. Management's execution on clinical and regulatory milestones will be key to unlocking shareholder value.

Upcoming Catalysts (preview)

• Q3 2026FDA approval decision for Eroxon in the US70% success
• Q4 2026Partnership or licensing agreement for Eroxon in Asia-Pacific60% success
• Q2 2026First full quarter of Eroxon sales in Europe post-commercial launch80% success